SLNO Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own SLNO shares is 208, representing 100.95% of the company's common stock.

NANTAHALA CAPITAL MANAGEMENT, LLC, in the last quarter, reduced its stake in SLNO by -15.61% restricting it's holding to 2.41 million shares of worth nearly $103.16M. SAMLYN CAPITAL, LLC also lessened -27.45% of the SLNO shares from its portfolio, reducing its holding to 218.93 thousand shares of worth $9.37M. COMMODORE CAPITAL LP also shunned SLNO shares holding by -75.78% last quarter which brought its holding to 169.53 thousand shares worth $7.26M.

As per its latest 13F filing, CANNON GLOBAL INVESTMENT MANAGEMENT, LLC increased its stake in SLNO by 100% in the last quarter. The institutional holder raised its holding to 11.8 thousand shares having worth more than $505.04K. STATE OF WISCONSIN INVESTMENT BOARD also added 17.17% more shares of SLNO to its portfolio, raising its holding to 11.13 thousand shares of worth $476.19K. HIGHVISTA STRATEGIES LLC also increased its SLNO shares holding by 100% which brought its holding to 10.43 thousand shares worth $446.32K.

The insider with the most stakes in SLNO is Vivo Opportunity, LLC , 10 percent owner at the company. Additionally, SLNO stock is highly held by 10 percent owner Carlyle Group Inc. and CHIEF EXECUTIVE OFFICER Anish Bhatnagar among others.

Company executives, directors, and other insiders own 3.05% percent of Soleno Therapeutics, Inc.'s stock. Within the last six months, there have been 31 transaction(s) in which SLNO insiders have sold stock, totaling 1.18M shares. Insiders that have sold shares include ANISH BHATNAGAR, YEN KRISTEN, and MACKANESS JAMES H.

There have been 0 transaction(s) during the past 6-months in which Soleno Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 27.26M Soleno Therapeutics, Inc. shares are held by insiders, which represents about 3.05% of SLNO stock.

SLNO 10 percent owner, Vivo Opportunity, LLC holds the largest portfolio of the company's shares. SLNO shares owned by Vivo total nearly 6.29 million.

CANNON GLOBAL INVESTMENT MANAGEMENT, LLC is the largest institutional owner in SLNO which holds 11.8 thousand shares worth $505.04K or 0.03% of the total SLNO shares outstanding followed by STATE OF WISCONSIN INVESTMENT BOARD with ownership of 11.13 thousand shares representing 0.03% of the SLNO ownership. HIGHVISTA STRATEGIES LLC is the third largest stakeholder with 10.43 thousand shares or 0.03% of the ownership worth more than $446.32K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the SLNO is concerned, it is a stock which is optionable.

Number of SLNO shares short is 4.59M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 43.12M shares of SLNO are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, SLNO has 27.54M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for SLNO is 6.81.